https://prabadinews.com/
  • October 8, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Approves Donidalorsen as First RNA-Targeted Prophylactic Treatment for Hereditary Angioedema

FDA Approves Donidalorsen as First RNA-Targeted Prophylactic Treatment for Hereditary Angioedema

The FDA approves donidalorsen, the first RNA-targeted therapy for hereditary angioedema, offering significant attack reduction and convenient administration.

administrator

Related Articles